# A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation

> **NCT07023731** · PHASE1,PHASE2 · RECRUITING · sponsor: **Arvinas Inc.** · enrollment: 159 (estimated)

## Conditions studied

- KRAS G12D Mutation
- Advanced Solid Cancer

## Interventions

- **DRUG:** ARV-806

## Key facts

- **NCT ID:** NCT07023731
- **Lead sponsor:** Arvinas Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-29
- **Primary completion:** 2027-11-30
- **Final completion:** 2029-04-02
- **Target enrollment:** 159 (ESTIMATED)
- **Last updated:** 2026-02-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07023731

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07023731, "A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07023731. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*